*Limitations*

The main limitation of this study was the absence of a control group. Of note, since the sample size was small—because the study design was a continuation of previous work and mostly for ethical reasons, all 29 participants were assigned to a single experimental group so that this population, which was especially vulnerable to COVID-19, received effective treatment during this trial. Although the positive eating behavior, PA, BMI, and BP results were similar to those obtained in our previous 'Living Better' randomized controlled trial, the absence of a control group must be considered when interpreting the effects of this reintervention. In addition, although, prior to reintervention, we were unable to identify any differences in the variables in the 29 participants and the 76 patients excluded from the study, we cannot rule out the possibility of a selection bias. Therefore, these findings should be interpreted with caution. Finally, the participants were unable to go to the hospital for BMI and BP measurements before and after the reintervention because of the COVID-19 pandemic restrictions. However, this problem was mitigated by having these measurements completed by the same person (a pharmacist or pharmacy assistant) using

the same approved devices both times, and strictly following the ESH protocol, as in the first intervention.
